Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 9.75p 9.50p 10.00p 9.75p 9.75p 9.75p 123,178 07:47:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 7.49

N4 Pharma (N4P) Latest News (1)

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
18/12/201712:32N4 Pharma - Making good drugs better.732
10/11/201710:48N4 Pharma55

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 9.75p.
N4 Pharma has a 4 week average price of 7.25p and a 12 week average price of 5.25p.
The 1 year high share price is 12.38p while the 1 year low share price is currently 4.75p.
There are currently 76,785,714 shares in issue and the average daily traded volume is 726,799 shares. The market capitalisation of N4 Pharma is £7,486,607.12.
stephen2010: Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
biggest bill: Ivor, this is aim. Anything can happen to a company's share price.
escapetohome: An unacceptable share price performance
biggest bill: Flexton, your first post on N4P was on 1/8/17 and you have certainly not made a correct prediction about the share price here. Your many subsequent posts here have been ridiculous to put it mildly. For somebody who claims to hold shares here (which I don't believe for a minute), your behaviour has been bizarre.
zebbo: "Inherent value here is way above the current share price". Value is way way above current share price and then some. I am going to partake in the 1000% ++ rise that is expected over the next few years. Get in early and then place in bottom draw, thats how real money is made Side note - Also not sure who wrote the last RNS as it was poorly worded and just left a load of questions unanswered and failed to highlight the commercial aspects
bones: For those clearly demoralised investors who can now only see downsides (even to today's progress announcement!) due to the depressed share price should remind themselves of the array of IP and future potential that N4P possesses. Not only that but the scaremongerers saying that the company will always be seeking cash have to remember that there are warrant holders who may put in £1.8m at 8p per share over the next two years plus the company will receive plenty of grants from UK bodies like Innovate UK that helps small companies with promising developments in science. No-one is saying that, in the future, no further funds will be needed from the market but that is common for pharma cos. There are companies on Nasdaq that only earn from milestones from large pharma yet are valued in billions of dollars. Perhaps these Youtube clips might help refocus on why you are invested (and not trading) and then forget about daily movements and market swings. N4P is today valued in total at less than £5m. Crazy huh?
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
bones: Zebbo, I note that Pfizer article was published over two months ago so doesn't seem to have harmed N4P price since then.You say N4P could be in the right place at the right time but do you not think Pfizer could be a giant to be fighting here?I know that N4P are aware that, in any generic post-patent space, competition will be plentiful but that there should be room for everyone who has a decent improvement. Question for me is would Pfizer look to the likes of N4P to licence from or would it use its clout to do everything itself and squeeze smaller competitors?I do not have the answers, by the way :)
darkinbad: Ch1rp, a double top is a technical indicator. The share price has established resistance at 9.625 so if the share price approaches it and fails to push through, pulling back with a lower end of day price, it then effectively establishes two consecutive high points at the resistance level - 'a double top'. If one does form, the share price may pull back further, possibly going to the recently established support at 8.25.
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171218 18:29:19